Stock KRRO KORRO BIO, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Korro Bio, Inc.

Equities

KRRO

US5009461089

Market Closed - Nasdaq
Other stock markets
 21:00:00 15/05/2024 BST 		5-day change 1st Jan Change
52.77 USD +5.43% Intraday chart for Korro Bio, Inc. +0.86% +10.10%
05-15 HC Wainwright Adjusts Korro Bio's Price Target to $100 From $115, Keeps Buy Rating MT
05-14 Korro Bio Q1 Net Loss Shrinks; Kemi Olugemo Appointed as Chief Medical Officer MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
HC Wainwright Adjusts Korro Bio's Price Target to $100 From $115, Keeps Buy Rating
MT
Korro Bio Q1 Net Loss Shrinks; Kemi Olugemo Appointed as Chief Medical Officer
MT
Korro Bio : Q1’24 Corporate Presentation
PU
Korro Reports First Quarter 2024 Financial Results and Appointment of Kemi Olugemo, M.D. as Chief Medical Officer
AQ
Korro Bio, Inc. Announces the Appointment of Kemi Olugemo, M.D. as Chief Medical Officer
CI
Korro Bio Insider Bought Shares Worth $999,992, According to a Recent SEC Filing
MT
Korro Bio Insider Bought Shares Worth $999,992, According to a Recent SEC Filing
MT
Korro Bio Insider Bought Shares Worth $999,992, According to a Recent SEC Filing
MT
Korro Bio Insider Bought Shares Worth $999,992, According to a Recent SEC Filing
MT
Korro Bio Insider Bought Shares Worth $999,992, According to a Recent SEC Filing
MT
Korro Bio Insider Bought Shares Worth $999,992, According to a Recent SEC Filing
MT
Korro Bio Insider Bought Shares Worth $999,992, According to a Recent SEC Filing
MT
Korro Bio, Inc. announced that it has received $69.959848 million in funding from Atlas Venture L.P., Deep Track Capital, LP, Blue Owl Healthcare Opportunities, Rock Springs Capital Management LP, Tri Locum Partners LP, New Enterprise Associates, Inc.
CI
Korro Announces $70 Million Private Placement
AQ
Korro Bio, Inc. announced that it expects to receive $69.959848 million in funding from Atlas Venture L.P.
CI
Korro to Participate in Upcoming Investor Conferences
AQ
HC Wainwright Adjusts Korro Bio's Price Target to $115 From $100, Buy Rating Kept
MT
RBC Boosts Price Target on Korro Bio to $90 From $70 on 'Increased Conviction for A1AT,' Keeps Outperform, Speculative Risk
MT
Korro Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Korro Reports Full Year 2023 Financial Results and Highlights Recent Progress
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. KRRO Stock
  4. News Korro Bio, Inc.